Publication
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.
Authors not recorded
Proc Natl Acad Sci U S A2005PMID 15647370PMC545580stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugSirolimuscivic_curation1.00
- genePIK3CAcivic_curation1.00
- variantPIK3CA E542Kcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 15647370
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PIK3CA E542K1 | ||||||||
| Sirolimus | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID311Rapamycin inhibits transformation induced by mutation in PIK3CA. PMID 15647370 · Kang et al., 2005 · Open in CIViC | civic |